2024584-38-9

Seletracetam (intraperitoneal injection) lithium bromide displays potent protection against secondary generalised motor seizures in fully corneally-kindled mice (ED₅₀ 0.31 mg/kg). In audiogenic seizure susceptible mice, Seletracetam (i.p) protects against clonic convulsion expression with an ED₅₀ of 0.17 mg/kg^[3].
Seletracetam (0.0074 mg/kg to 74 mg/kg; intraperitoneal injection) lithium bromide increases the generalized seizure threshold current and decreases the duration of the after-discharge and the seizure severity observed at the after-discharge threshold current, and generally has a much more potent effect than previously observed for Levetiracetam^[3].